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1376Objective: Thrombin has been reported to play a pivotal role in the initiation of angiogenesis by indirectly
regulating and organizing a network of angiogenic molecules. On the basis of these reports, we investigated
the angiogenic action of thrombin in a rabbit model of acute myocardial infarction.
Methods:A rabbitmodel of acutemyocardial infarctionwas established by ligation of the left anterior descending
coronary branch. Subjects were then divided into 2 groups and treated with intramyocardial administration of
thrombin (2500 IU; n¼ 13) or an equal volume of normal saline (n¼ 13). Four weeks later, animals were eutha-
nized and histopathologic analysis, immunohistochemical staining for endothelial markers CD31 and vascular
endothelial growth factor-A, and electron microscopy examination were performed on excised hearts. Electrocar-
diography, cardiac enzymes, and assessment of cardiac function by measuring left ventricular end-diastolic
pressure and ejection fraction were recorded before and after myocardial infarction, and both left ventricular
end-diastolic pressure and ejection fraction were further measured on the day of euthanasia (n¼ 5-8 in each case).
Results: Increased levels of troponin, ST elevation, and histopathologically confirmed myocardial infarction
were observed in all animals. A significant increase of microvessel density at the infarct border zone, as eval-
uated by CD31 immunohistochemistry, was observed in the thrombin-treated group compared with the control
group (30.3  12.8 vs 12.6  4.8, P ¼ .0065). A significantly higher number of vascular endothelial growth
factor-A–positive vessels at the infarct border zone was observed in the thrombin-treated animals compared
with the control group (21.8 8.9 vs 5.6 4.4; P¼ .0009). The thrombin-treated animals showed a statistically
significant reduction in left ventricular end-diastolic pressure values (6.9  1.8 mm Hg vs 12.7  2.2 mm Hg,
P¼ .0002) and significant improvement in left ventricular ejection fraction (59.8% 3.1% vs 42.2% 6.14%,
P¼ .002) on the day of euthanasia compared with the post-infarct day, reflecting significantly improved cardiac
function compared with control subjects that showed no significant change.
Conclusions: Intramyocardial administration of thrombin seems to promote angiogenesis and improve cardiac
function of the ischemic myocardium, which may provide a new therapeutic approach in patients with myocar-
dial ischemia. (J Thorac Cardiovasc Surg 2014;147:1376-83)Coronary artery disease is the major cause of death in the
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The Journal of Thoracic and Cardiovascular Surextensively studied topics in modern cardiovascular
research. The open-chest animal platform is one of the
most well-developed models of myocardial infarction in
modern laboratories of cardiovascular research.3 Despite
major advances in the prevention and treatment of athero-
sclerotic vascular disease, a large number of patients with
advanced symptomatic coronary artery disease have dis-
abling symptoms despite pharmacotherapy and revascular-
ization by coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty. It is well known that
coronary collateral vessels protect myocardial tissue from
ischemic injury.4 Therapeutic myocardial angiogenesis is
a novel approach based on the development of new blood
vessels in ischemic regions under the influence of the appro-
priate growth factors.5 Treatment of coronary disease using
growth factors that augment vessel growth is increasingly
proposed for otherwise untreatable patients either alone or
in combination with other procedures. Successful preclini-
cal studies and promising early results in clinical trials havegery c April 2014
Abbreviations and Acronyms
AMI ¼ acute myocardial infarction
CAM ¼ chick chorioallantoic membrane
ECG ¼ electrocardiography
IM ¼ intramuscularly
LAD ¼ left anterior descending
LVEDP ¼ left ventricular end-diastolic pressure
LVEF ¼ left ventricular ejection fraction
MVD ¼ microvessel density
PB ¼ phosphate buffer
VEGF ¼ vascular endothelial growth factor
Mitsos et al Evolving Technology/Basic Sciencecreated excitement about the potential of coronary thera-
peutic angiogenesis.6 Many angiogenic growth factors
have been identified, but few have been tested in clinical tri-
als and most trials have focused on vascular endothelial
growth factor (VEGF) and fibroblast growth factor with
controversial results.5-7
Apart from its central role in blood coagulation, thrombin
is also claimed to be a potent activator of angiogenesis. The
angiogenic action of thrombin has been demonstrated in the
chick chorioallantoic membrane (CAM) system8 and the
in vivoMatrigel system.9 This is a thrombin receptor–medi-
ated event and is independent of fibrin formation. Throm-
bin, unlike other angiogenic factors, has a multiplicity of
effects on angiogenesis and plays a significant role in regu-
lating vascular functions, vascular stability, promotion of
endothelial cell survival and interaction with other factors,
and many cell types. Consequently, thrombin may have
the unique ability to orchestrate the requirements for the
formation of mature blood vessels andmay have therapeutic
angiogenic applications. In the present study, we investi-
gated the effects of direct intramyocardial administration
of thrombin and its ability to induce vessel growth in a rabbit
model of acute myocardial infarction (AMI).E
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This investigation was carried out in conformity with the ‘‘Guide for the
Care and Use of Laboratory Animals’’ published by the National Institutes
of Health (publication No. 86-23, revised 1985) and approved by the local
University Hospital’s Scientific and Ethical Committee. New Zealand
White rabbits weighing 2.5 to 3.5 kg were kept in separate cages in an en-
vironmentally controlled animal research facility. The experimental proto-
col included 2 groups: (1) a group of animals that underwent tracheostomy,
subxiphoid incision, left anterior descending (LAD) artery ligation with
suture, and intramyocardial administration of thrombin, and (2) a control
group of animals that underwent tracheostomy, subxiphoid incision,
LAD artery ligation with suture, and intramyocardial administration of
saline 0.9% NaCl.
Experimental Model of Acute Myocardial Infarction
All procedures were performed with the animals under anesthesia, with
a mixture of ketamine (35 mg/kg) and xylazine (5 mg/kg) administered in-
tramuscularly (IM).10 Subsequent anesthesia was maintained with lowThe Journal of Thoracic and Cardoses of propofol. The surgical procedure was performed in a sterilized
fashion. The subxiphoid region was clipped and shaved, followed by sterile
surgical draping. A 22-gauge intravenous catheter was inserted into the
marginal ear vein for venous access. The animals were placed on a heating
pad in the supine position, and an intravenous normal saline drip (15 mL/h)
was established.
Immediately before ligation, 1 mg/kg of lidocaine was administered in-
travenously to minimize potential ventricular arrhythmias. A prophylactic
antibiotic (cefuroxime 35 mg IM) was administered before and after sur-
gery, and an analgesic was given postoperatively. Electrodes for electrocar-
diography (ECG) were attached in both the front limbs and the lower
abdomen at bilateral positions. Arterial oxygen saturation was measured
with a standard pulse oximeter. The ECG, systemic blood pressure, and
pulse oximetry were monitored continuously during surgery. A tracheos-
tomy was performed, and subjects were ventilated with room air through
a 3.5-mm pediatric tracheal tube at a rate of 35 to 40 breaths/min and a tidal
volume of 10 to 15 mL using room air enriched with oxygen. The trache-
ostomy tube was removed after the end of the experimental surgical
procedure.
Tomimic clinically relevant coronary artery disease, we used amodel of
myocardial infarction. A skin incision was made over the subxiphoid re-
gion and sternum. The xiphoid process was carefully detached from the
sternal part of diaphragm. A mini median sternotomy was performed care-
fully along themidline to avoid injury to the parietal pleura.11,12 The sternal
edges were spread, and an incision was made at the cardiac sac to expose
the myocardial ventricular wall. A 5-0 monofilament polypropylene suture
was placed around the LAD coronary artery approximately 8 to 10 mm
from its origin. Within 5 minutes after coronary occlusion, rabbits were
divided into 2 groups. In the thrombin group, bovine-derived thrombin
(FloSeal; Baxter Healthcare Corp, Vienna, Austria) was injected using
a thin 27-gauge needle into the myocardium at the ischemic area of the
left ventricular wall. Thrombin 2500 IU was diluted in 0.5 mL of solution
and administered slowly with 5 separate injections (0.1 mL per injection).
Injections were equally distributed along the ischemic myocardium with
a radius of a few millimeters between each other.
There were no changes in blood pressure or heart rate associated with
the injection of thrombin and no obvious adverse effects, such as anaphy-
lactic reaction, in rabbits throughout the experiment. In control rabbits, an
equal volume of saline (0.5 mL) was injected in the same manner. After he-
modynamic stability, the sternum, muscle layers, and skin were closed, and
rabbits were allowed to recover. During surgery, an 18-gauge catheter was
inserted into the left ventricle via the left ventricular apex for continuous
measurement of left ventricular end-diastolic pressure (LVEDP) and was
removed after successful induction of myocardial infarction. Two-
dimensional and M-mode echocardiographic images were obtained via
a right parasternal approach to determine the ejection fraction because
the best acoustic window could be acquired from the right parasternal po-
sition that provided long and short-axis views of the left ventricle equiva-
lent to the left parasternal window in humans. Serum levels of aspirate
aminotransferase, lactate dehydrogenase, creatine kinase, and MB isoen-
zyme of creatine kinase and troponin were measured with a microparticle
enzyme immunoassay (MEIA AxSYM; Abbott Laboratories, Abbott Park,
Ill) and Liaison assay before and 3, 6, 12, and 24 hours after ligation to as-
sess irreversible myocardial injury invoked during the procedure.Histopathologic Analysis
Four weeks after ligation of the LAD artery, the rabbits were anesthe-
tized again with ketamine (35 mg/kg) and xylazine (5 mg/kg) IM. A me-
dian sternotomy was performed, and adhering tissue was carefully
removed around the myocardium. Heparin (1000 U) was given intrave-
nously to prevent clotting. An 18-gauge catheter was reintroduced through
the ventricular apex, and LVEDP measurements were taken before eutha-
nasia as described previously. All subjects were then euthanized with an
overdose of propofol, and hearts were excised along with the aortic root.diovascular Surgery c Volume 147, Number 4 1377
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the infarct area is easily identified and delineated macroscopically 4 weeks
after the ischemic injury.13,14 After macroscopic examination, 3-mm–thick
sections were taken at the greatest dimension of clearly identifiable ‘‘gray-
white’’ post-infarct fibrotic areas, fixed in 10% formalin, and embedded in
paraffin. Sections (4 mm) from paraffin-embedded blocks were stained with
hematoxylin–eosin and Masson trichrome staining for histopathologic
analysis.
Immunohistochemistry
Anti-CD31 is a widely used and reliable method for assessing angiogen-
esis.15,16 Immunohistochemical analysis was performed using a standard
biotin-streptavidin-peroxidase method. Sections (4 mm) from paraffin-
embedded blocks were subjected to de-paraffinization, rehydration, and
antigen epitope retrieval withDAKO target retrieval solution pH 9 in a pres-
sure cooker (pretreatment; DAKO, Glostrup, Denmark) for 15 minutes at
90C. Endogenous peroxidase activity was blocked with 1% hydrogen per-
oxide for 15 minutes. To reduce nonspecific background staining, slides
were incubated with protein-blocking solution (goat serum) for 10minutes.
Sections were then incubated with the mouse monoclonal anti-CD31 anti-
body (endothelial cell clone JC70A, DAKO) at 1:40 dilution for 30minutes
at room temperature and mouse monoclonal anti-VEGF (BD Biosciences,
Franklin Lakes, NJ) dilution 1:50 overnight at 4C. Bound primary anti-
body was detected using the UltraVision horseradish peroxidase mouse
(Neomarkers; Lab Vision, Fremont, Calif) according to the manufacturer’s
instructions. Diaminobenzidine was used as the chromogen for visualiza-
tion. Slides were counterstained with hematoxylin, dehydrated, and
mounted. To test the specificity of the antibody, the same protocol was ap-
plied by replacing the primary antibody with protein blocking solution
(negative control).15-17 For the assessment of microvessel density (MVD)
based on CD31 immunostaining, infarct area, border zone, and remote
area in each case were evaluated separately. The areas of highest
vascularization (hot spots) were chosen at low power (3100) and
microvessel counting followed on 3 chosen high-power fields. The re-
cordedMVDwas the median of the vessel counts obtained in these 3 fields.
Counting of vessels positive for VEGF-A expression was performed simi-
lar to MVD.
Transmission Electron Microscopy
Glutaraldehyde, propylene oxide, epoxy resins, and lead citrate were
obtained from Serva (Heidelberg, Germany). The salts for the preparation
of phosphate buffer (PB) and the absolute ethanol were obtained from
Merck (Whitehouse Station, NJ). Uranyl acetate and osmium tetroxide
were obtained from Polyscience (Warrington, Pa). The diamond knife
was obtained from Diatome Ltd (Biel, Switzerland). All the photographic
material, such as films, developer, and fixer solutions, were obtained from
Kodak (New York, NY).
Tissue specimens were collected immediately after the subjects were
killed. Small pieces of the tissues (1.5-2 mm3) were cut and immediately
immersion-fixed for 3 hours at 4C in Karnovsky fixative containing 3%
glutaraldehyde, 1% formaldehyde in PB 0.1 mol/L, pH 7.4. The tissue
pieces were washed in 3 changes of PB and post-fixed in 2% aqueous os-
mium tetroxide for 2 hours at 4C. The specimens were then dehydrated
with increasing concentrations of ethanol (for 10 minutes each in 25%,
50%, 70%, and 95% ethanol and for 10 minutes in 100% ethanol twice),
followed by propylene oxide (2 changes, 5 minutes each), infiltrated
gradually in a mixture of Epon/Araldite resins diluted in propylene oxide
(1:2, 1:1, 2:1, 1 hour each) and then embedded in fresh epoxy resin mixture.
Finally, the specimens were allowed to polymerize at 60C for 24 hours in
an oven.
For electron microscopy, ultrathin (80-90 nm thickness) sections were
cut with a Diatome Ltd diamond knife on a Leica (Wetzlar, Germany)
Ultracut R ultramicrotome and collected onto 200-mesh uncoated copper
grids. The grids were counterstainedwith saturated ethanolic uranyl acetate1378 The Journal of Thoracic and Cardiovascular Surand lead citrate. Sections were viewed in a Zeiss EM 900 (Carl Zeiss Med-
itec, Jena, Germany) electron microscope, at 80 kV accelerating voltage,
with an objective aperture of 30 mm. The electron micrographs were re-
corded on Kodak Electron Image film SO-163 (gelatin plates, 8 cm 3 10
cm, Code No: 1679257) and then developed with the Kodak D-19 devel-
oper. The negatives were scanned with aMikrotek (Santa Fe Springs, Calif)
ScanMaker 9800XL scanner using optical resolution of 1000 ppi and stored
as tiff files.When required, the digitized images were printed at 1200 dpi on
an HP Laserjet 4250n high-resolution laser printer (Hewlett Packard Co,
Palo Alto, Calif).
Statistical Analysis
Discrete variables were provided as counts and percentages, and contin-
uous variables were given as medians and interquartile ranges (25th-75th
percentiles) or as means  standard deviation if they originated from
normal distributions. The unpaired Student t test was used to test the
significance of difference of variables that passed the normality test. The
chi-square test was used for testing of qualitative variables, and the
Mann–Whitney test was used for nonparametric testing of continuous
variables that did not pass the Kolmogorov–Smirnov normality test.RESULTS
Electrocardiography and Blood Biochemistry
ECG of all rabbits was normal on baseline. ST-segment
elevation, an indicator of severe ischemia or ongoing infarc-
tion of full-thickness myocardium, was seen in each animal
almost immediately after occlusion of the LAD artery. In
total, 21 of 24 animals survived after suture placement
around the LAD coronary artery producing total LAD oc-
clusion. Another 5 animals died after being randomized to
a treatment group. There were 3 deaths in the thrombin
group (3/11) and 2 deaths in the control group (2/10).
Two of the subjects died of ventricular fibrillation after
quick intramyocardial injections (1 control animal and 1
thrombin animal). The next 2 deaths were recorded 24 hours
after intramyocardial administration (1 control subject and
1 thrombin subject). One rabbit in the thrombin group had
a late death within the first 10 days after myocardial infarc-
tion due to sepsis. Overall experimental mortality rate was
33.3% (8/24), and as a result 8 subjects were included in
each study arm. Four weeks after myocardial infarction,
ECG showed abnormal Q waves in all surviving animals.
There was no statistically significant difference in the
ST-elevation between the 2 groups (Figure 1).
Myocardial ischemia was confirmed with a significant in-
crease of aspirate aminotransferase, lactate dehydrogenase,
creatine kinase, MB isoenzyme of creatine kinase, and tropo-
nin T after occlusion of coronary artery compared with base-
line values. Therewas no statistically significant difference in
myocardial-enzyme changes in blood serum 24 hours after
LAD occlusion between the 2 groups (data not shown).
Serum troponin-T levels before induction of infarction were
less than 0.2 ng/mL in both groups. Troponin-T levels were
significantly increased 24 hours after coronary occlusion in
both the thrombin and control groups, but therewas no signif-
icant difference between the 2 groups (49.6 65.1 ng/mL vs
40.0  57.1 ng/mL, respectively, P ¼ .76; Figure 1).gery c April 2014
FIGURE 1. ECG and troponin. Myocardial ischemia was confirmed by
ST-segment elevation on ECG in all subjects. Therewas no statistically sig-
nificant difference between the 2 groups with regard to ST-segment eleva-
tion (left) or troponin T levels at 24 hours (right). THR, Thrombin-treated
group.
Mitsos et al Evolving Technology/Basic ScienceHistologic Examination
Histolopathologic analysis of heart sections confirmed
the presence of myocardial infarction in both groups.
Granulation tissues with new blood vessels, infiltration by
lymphocytes, plasma cells, histiocytes, and collagen depo-
sition were identified at the site of myocardial infarction.
Infarct size was measured on sections stained withFIGURE 2. Histologic examination. Masson trichrome staining (A and D) of m
(A; top) and control group (D; bottom) are presented (magnification340). CD3
ments. Representative cases of thrombin-treated (B; top) and control group (E; b
border zone. Representative cases of thrombin-treated (C; top) and control gro
The Journal of Thoracic and Carhematoxylin–eosin and Masson trichrome that were taken
at the greatest dimension of macroscopic gray-white areas
(Figure 2). Myocardial infarct size was 0.8 0.4 cm (range,
0.6-1.7 cm) in the thrombin-treated group and 0.9 0.2 cm
(range, 0.6-1.2 cm) in the control group. There was no sta-
tistically significant difference in the size of the myocardial
infarct area between the 2 groups (P ¼ .49). Given the
hypothesis that the tissue stimulus for angiogenesis is
more intense in tissues adjacent to the infarct zone, MVD
was examined in the border zone of the infarct with anti-
CD31 immunostaining. Recorded MVD was significantly
higher in the infarct border zone of thrombin-treated hearts
and numerically more than double the one recorded in the
control group (30.3  12.8 vs 12.6  4.8, respectively;
P ¼ .0065) (Figure 3). VEGF-A expression was observed
in endothelial cells and macrophages. The recorded number
of VEGF-A positive vessels at the infarct border zone was
significantly higher in thrombin-treated animals compared
with the control group (21.8  8.9 vs 5.6  4.4;
P ¼ .0009; Figure 2).Transmission Electron Microscopy
In samples distant to infarction, myocytes appeared
nearly normal. Sarcomeres showed a normal pattern, and
most of the mitochondria were oval with a granular,
electron-dense matrix with typical orderly arranged cristae.
Signs of ischemic injury were not visible (Figure 4, A). On
the contrary, in ischemic areas, extended intracellularyocardial infarct in the 2 groups. Representative cases of thrombin-treated
1-immunostaining of vessels at the infarct border zone for MVD measure-
ottom) (magnification3400). VEGF-A expression in vessels at the infarct
up subjects (F; bottom) (magnification 3400).
diovascular Surgery c Volume 147, Number 4 1379
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FIGURE 3. MVD and infarct size. MVD measured at the infarct border
zone was significantly higher in the hearts treated with 2500 IU thrombin
compared with the saline-treated control group (left; *P< .05). Histo-
morphometry of the myocardial infarct area shows a similar extent of
necrosis in the 2 groups (right). THR, Thrombin-treated group.
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almost completely disorganized, and mitochondria ap-
peared as dense irregular structures with disordered frag-
ments of cristae (Figure 4, B). After myocardial
infarction, a mild injury was visible in the border zone of
the thrombin-treated group. Tissue consisted of a more or
less regular pattern of sarcomeres with I-bands misaligned
to a significant extent and slightly disordered mitochondria
with dense grainy matrix. A slight intracellular edema was
seen. High-resolution electron micrographs showed that in
the border zone of thrombin-treated hearts, signs of neovas-
cularization were visible by the formation of small exten-
sions of the capillary walls (Figure 4, C). Untreated
tissues appeared to have significant damage in the border
zone with disordered myofilaments exhibiting signs of
contraction or relaxation, but compared with the
thrombin-treated samples, they showed less signs of
neovascularization (Figure 4, D).Hemodynamic Measurements
Cardiac function was assayed by recording LVEDP and
left ventricular ejection fraction (LVEF), which were mea-
sured before and after myocardial infarction and on the day
of euthanasia, offering an indication of left ventricular sys-
tolic function. The main effects of infarction were a signifi-
cant increase of LVEDP and significant decrease of LVEF in
all infarcted subjects because of myocardial dysfunction. At
baseline, LVEDP and LVEF were 7.1  1.7 mm Hg and
68.2%  4.7%, respectively, in the thrombin group, and
6.7  1.3 mm Hg and 69.6%  3.8%, respectively, in the
control group. LVEDP and LVEF changed to 12.7  2.2
mm Hg and 42.2%  6.1%, respectively, in the thrombin1380 The Journal of Thoracic and Cardiovascular Surgroup, and to 12.2  2.3 mm Hg and 42.8%  7.2%, re-
spectively, in the control group soon after induction of
AMI. However, on the day of euthanasia the thrombin-
treated animals showed a statistically significant reduction
in LVEDP (6.9  1.8 mm Hg vs 12.7  2.2 mm Hg,
P ¼ .0002) and significant increase in LVEF (59.8 
3.1% vs 42.2  6.1%, P ¼ .002) compared with the
post-infarct day, reflecting recovery of cardiac function
most likely due to increased regional coronary angiogene-
sis, whereas no change was noted in the control group
(Figures 5 and 6).
DISCUSSION
In the present study, a single intramyocardial injection of
thrombin in a rabbit model of AMI enhanced the angiogenic
response to ischemia with a significant increase of regional
collateralization. These benefits were accompanied by im-
provements in cardiac systolic function in the ischemic ter-
ritory. New collaterals were developed to protect the
ischemic myocardium from injury. This native arteriogenic
responsewas profoundly augmented by thrombin with a sta-
tistically significant increase of MVD and VEGF expres-
sion compared with the control group. Although there was
not a significant decrease of infarct size in the thrombin
group, a statistically significant restoration of heart function
as indicated by reduction of LVEDP and increase of ejection
fraction in the thrombin group was noted. The improvement
in cardiac function probably resulted from a combination of
factors, including improvement of local myocardial perfu-
sion and contractility. In theory, the contractile function of
hibernating myocardium may be improved by the improve-
ment of myocardial perfusion with angiogenesis. To our
knowledge, this is the first experimental study to investigate
the angiogenic action of thrombin in the acutely ischemic
myocardium.
Our results are in linewith previously described effects of
thrombin administration and build further on previous
reports indicating that thrombin functions as a potent
proangiogenic molecule. Tsopanoglou and colleagues8 sug-
gested that thrombin can promote angiogenesis in the CAM
system and that the functional catalytic site of thrombin is
required. The ability of thrombin to stimulate the formation
of vessels has been shown in the Matrigel in vivo model.9
Moreover, Dimitropoulou and colleagues18 reported that
thrombin caused significant increases in the numbers, diam-
eters, and lengths of capillaries in the CAM system. Many
cellular effects of thrombin on endothelial cells can contrib-
ute to the angiogenic action of thrombin.19,20 Thrombin
decreases the ability of endothelial cells to attach to
basement membrane proteins. Thrombin upregulates the
expression of avb3 integrin,21,22 which is the marker of
the angiogenic phenotype of endothelial cells and serves
as a ligand to this receptor.23 Furthermore, thrombin in-
creases the secretion of VEGF and enhances the expressiongery c April 2014
FIGURE 4. Transmission electron microscopy. Examples images of (A) remote zone and (B) infarct area after experimental myocardial infarction in the
New Zealand White rabbit. Representative transmission electron microscopy images of (C) capillary sprouting on the border zone of the thrombin group,
compared with images of (D) capillaries on the border zone of the control group. Note the improved neovascularization in the infarct border-zone of
thrombin-treated rabbit hearts compared with saline-treated control cases (C and D).
Mitsos et al Evolving Technology/Basic Science
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Moreover, thrombin has chemotactic and haptotactic
effects on endothelial cells and upregulates the expression
of VEGF receptors (kinase insert domain-containing recep-
tor and fms-like tyrosine kinase).23-25 Thus, thrombin
synergizes with the key angiogenic factor VEGF in
endothelial cell proliferation. Thrombin itself and its
receptor protease-activated receptor 1 orchestrate many cel-
lular events through interaction with a variety of other fac-
tors and cell types 1 and play a potential role in the
complexity of the regulatory processes involved in the an-
giogenic cascade.26,27 Thrombin protects endothelial cells
from apoptosis through a mechanism mostly independent
of its catalytic active site and PAR1 activation, whereas
the integrins anb3 and a5b1 play an essential role in
thrombin-induced cytoprotection.28 Katsanos and col-
leagues29 have recently shown that thrombin promoted arte-
riogenesis and improved the perfusion of distal ischemic
tissue in a rabbit hind-limb ischemia model. It was demon-
strated that a single intramuscular injection of thrombin
caused a significant increase of regional collateralizationThe Journal of Thoracic and Carand enhanced distal blood flow circulation, and resulted in
both angiographically and functionally better vasculature
in the rabbit hind-limb ischemic model.29
The choice of thrombin concentration dose (2500 IU)
was based on its mean in vitro effective doses multiplied
by 1000. Our aim was to evaluate the effect of thrombin
in reasonable dose range from a clinical viewpoint. Throm-
bin was administered intramyocardially with 5 separate in-
jections. An advantage of intramyocardial administration of
thrombin may be that it strictly targets the area in need, in-
duces local angiogenesis, and seems to avoid high levels of
circulating angiogenic activity that could stimulate plaque
angiogenesis or growth of occult neoplasms. Opinions dif-
fer as to whether angiogenesis can be caused by a mere nee-
dle puncture of the myocardium.Mere mechanical needling
of the ischemic myocardium can induce vessel growth and
maintain function as shown by Chu and colleagues,30
whereas Horvath and colleagues31 did not observe this ef-
fect. Both experiments were done in porcine models of
myocardial ischemia in the context of transmyocardial
laser revascularization. In a clinical study, Pecher anddiovascular Surgery c Volume 147, Number 4 1381
FIGURE 5. LVEDPmeasurements (mmHg). Induction of AMI produced
a significant increase in LVEDP in both groups because of a disrupted car-
diac systolic function. Four weeks post-infarction, restoration of cardiac
systolic function was noted in the thrombin-treated hearts as evidenced
by normalization of the recorded LVEDP compared with no significant
change in the control group (*P< .05). LVEDP, Left ventricular end-
diastolic pressure; THR, thrombin-treated group.
FIGURE 6. LVEF measurements (%). Induction of AMI produced a sig-
nificant decrease of LVEF in both groups because of cardiac dysfunction.
Four weeks post-infarction, restoration of cardiac systolic function was
noted in the thrombin-treated hearts as evidenced by partial restoration
of the recorded LVEF compared with no significant change in the control
group (*P < .05). LVEF, Left ventricular ejection fraction; THR,
thrombin-treated group.
Evolving Technology/Basic Science Mitsos et al
E
T
/B
SSchumacher32 injected intramyocardial fibroblast growth
factor-1 or the heat denatured factor for control purposes.
The results showed the superiority of the active protein.
In the present study, both thrombin and saline were admin-
istered inside the myocardium using a thin 27G needle
exactly in the same manner. It is certain that different agents
require different applications to function optimally, and the
most effective application method might even differ for dif-
ferent growth factors depending on their cellular target.Study Limitations
First, thrombin was administered immediately after in-
duction of AMI. In the clinical setting, most patients receive
surgical procedures over the course of hours. It is necessary
to confirm the efficacy of thrombin administered at a longer
time after infarction. Moreover, it is possible that repeated
multiple injections of smaller doses or sustained release
of thrombin from biodegradable systems would be better
than bolus injection of high doses because new collateral
vessels require up to 20 days after the ischemic insult to
fully develop. Furthermore, we only counted the vessels
and did not measure their diameter. Therefore, additional
restructuring of small arterioles to larger vessels could
have eluded our observations. We did not evaluate histo-
logic specimens for microvascular thrombosis, but there
were no clinical sequelae to raise suspicion about a pro-
thrombotic status.1382 The Journal of Thoracic and Cardiovascular SurCONCLUSIONS
This study demonstrated the ability of locally adminis-
tered thrombin to induce new vessel growth and enhance
cardiac function when applied intramyocardially in a rabbit
model of AMI. Further studies arewarranted to look into the
therapeutic potential of thrombin in the setting of chronic or
acute myocardial ischemia by inducing therapeutic angio-
genesis and collateralization.
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